Profound MedicalPROF -1.77%73 EBIT per Share is $-1.22 as of Mar. 2026. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 690 Medical Devices & Instruments companies, Profound Medical ranks worse than 62.03% on this metric.
Profound Medical's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.22.
During the past 3 years, the average EBIT per Share Growth Rate was 0.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -4.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Profound Medical's EBIT per Share or its related term are showing as below:
PROF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -9.1 Med: 1.2 Max: 24.9
Current: 0.9
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Profound Medical was 24.90% per year. The lowest was -9.10% per year. And the median was 1.20% per year.
PROF's 3-Year EBIT Growth Rate is ranked worse than 62.03% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs PROF: 0.90
Profound Medical (NAS:PROF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Profound Medical EBIT per Share Related Terms
Profound Medical EBIT per Share Historical Data
* Premium members only.
The historical data trend for Profound Medical's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (PROF) has a EBIT per Share of $-1.22 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Profound Medical and its competitors. According to the industry distribution chart, Profound Medical ranks #428 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 62%.
Is Profound Medical's EBIT per Share too high?
Profound Medical's current EBIT per Share is $-1.22. Based on the distribution chart, Profound Medical ranks #428 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #428 out of 690 companies for EBIT per Share. This places Profound Medical in the lower half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current EBIT per Share is $-1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.21 — trading 49.5% below its estimated fair value. The current EBIT per Share is $-1.22. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Profound Medical (PROF), the current EBIT per Share is $-1.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.21 is trading 49.5% below its estimated GF Value™ of $14.28.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
EBIT per Share: $-1.22
GF Value™: $14.28 vs. price of $7.21 (49.5% below fair value)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
